Ruey‐Long Hong

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Barbara Burtness, Kevin J. Harrington, Richard Greil et al. · The Lancet · 2019 · 3.2K citations · Full text

Medicine, Oncology, Cancer Pharmacology +11

Multicenter, Phase II Study of Cetuximab in Combination With Carboplatin in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Anthony T.�C. Chan, Mow-Ming Hsu, Boon Cher Goh et al. · Journal of Clinical Oncology · 2005 · 292 citations · Full text

Medicine, Oncology, Pharmacology +17

Translocation of Liposomes into Cancer Cells by Cell-Penetrating Peptides Penetratin and Tat: A Kinetic and Efficacy Study

Yun-Long Tseng, Jun‐Jen Liu, Ruey‐Long Hong · Molecular Pharmacology · 2002 · 238 citations

Pharmacy, Pharmaceutics, Pharmacology +17

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16

Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

Roger B. Cohen, Jean‐Pierre Delord, Toshihiko Doi et al. · American Journal of Clinical Oncology · 2018 · 206 citations · Full text

Medicine, Oncology, Pharmacology +16